A New Option for Acute Migraine Relief: Introducing Symbravo
A few days ago, the FDA approved Symbravo, a novel, single-dose oral therapy for the acute treatment of migraine, with or without aura, in adults. What makes Symbravo unique is its multi-mechanistic approach to managing migraine attacks: it contains both meloxicam (an NSAID) and rizatriptan (a triptan).
What Is Symbravo?
Symbravo is designed to address several pathways involved in a migraine attack. Meloxicam is a long-acting NSAID formulated using a unique technology that allows it to be absorbed more quickly, while rizatriptan targets blood vessels and migraine pain pathways. Together, they work synergistically to provide rapid and sustained migraine pain relief after just one dose.
Proven Results
In clinical trials, patients achieved pain freedom and also experienced reduced symptoms such as sensitivity to light (photophobia), sound (phonophobia), and nausea. Sustained relief was reported through 24 and 48 hours after a single dose. What's interesting is that Symbravo outperformed rizatriptan and meloxicam taken separately.
Symbravo is not suitable for every migraine patient, as there are contraindications. Please consult your healthcare provider to determine whether you are a good candidate.
https://www.drugs.com/history/symbravo.html
